4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MacroGenics, Inc. (MGNX) operates in the Biotechnology industry and is headquartered in Rockville, United States with about 293 employees. Its market capitalization is roughly $288 million. In the fiscal year ended 2025-12-31, MGNX reported $150M in revenue and ($75M) in net income.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Interactive charts & full statements → Open the MGNX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $150M | $150M | $59M | $150M | — |
| Gross Profit | $114M | $138M | $50M | $143M | — |
| Operating Income (EBIT) | ($73M) | ($111M) | ($168M) | ($121M) | — |
| Net Income | ($75M) | ($67M) | ($9M) | ($120M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $21M | $41M | $73M | $22M | $13M | — |
| Gross Profit | $11M | $31M | $61M | $13M | $8M | — |
| Operating Income (EBIT) | ($33M) | ($12M) | $19M | ($37M) | ($43M) | — |
| Net Income | ($37M) | ($14M) | $17M | ($36M) | ($41M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $257M | $262M | $298M | $280M | — |
| Total Liabilities | $201M | $146M | $146M | $138M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MGNX viewer.
About TickerBase · Data methodology & sources